Peptides and autoimmune disease: why immune modulation cuts both ways

TL;DR

• "Immune support" is written for an immune system that is underperforming. In autoimmune disease the problem is the opposite: an immune response that is active, misdirected and aimed at the body's own tissue.
• Turning immune activity up in people with autoimmune disease has a measurable human cost. In cancer patients with pre-existing rheumatologic autoimmune disease, drugs that release the immune system's brakes were followed by a flare of that disease in roughly four in ten patients in a 2024 meta-analysis.
• Thymosin alpha-1 and LL-37 both act on the same machinery that drives autoimmunity. Thymosin alpha-1 primes dendritic cells through a Toll-like receptor while also promoting tolerance; LL-37 can convert the body's own DNA and RNA into an inflammatory alarm signal, a mechanism described in psoriasis and lupus.
• Whether immune-modulating peptides are safe in autoimmune disease is unestablished, not disproven. People with autoimmune conditions are rarely enrolled in the relevant trials, and the controlled studies that would answer the question have not been run or funded.
• The useful step is a specific conversation. The specialist managing the condition, usually a rheumatologist, holds the information that decides this: disease activity, antibody status, and the immunosuppressant plan already in place.

Educational content, not medical advice. No doses or protocols appear. Thymosin alpha-1 and LL-37 are not FDA-approved in the United States and are investigational in that setting. Nothing on this page is a recommendation to seek, purchase or use any compound.

---

A large share of peptide marketing is built on one word: support. Immune support, immune resilience, a "stronger" immune system. The pitch rarely says which part of the immune system is being strengthened, or against what, because it assumes a reader whose defences are tired.

For someone with rheumatoid arthritis, lupus, psoriasis, Hashimoto's thyroiditis, inflammatory bowel disease or multiple sclerosis, that assumption is wrong at the root. Their immune system is not tired. It has lost tolerance to part of their own body. This page explains why that changes the question, what the mechanistic evidence on two frequently discussed peptides shows, and why the answer for any individual has to come from the specialist who manages their condition.

This page sits alongside the compound pages for thymosin alpha-1 and LL-37, which cover each molecule's regulatory status and evidence in detail. It does not repeat them. Its job is narrower: the autoimmune exception.

What "immune modulation" actually means

"Immunomodulatory" is one of the least precise words in the peptide vocabulary. Strictly, it means a substance changes immune behaviour. It does not say in which direction, in which cell type, or for how long.

The immune system is not a single dial. It is a set of interacting arms with opposing jobs:

• Innate sensing, in which cells such as dendritic cells detect danger signals, including microbial DNA and RNA, through receptors such as the Toll-like receptors.
• Effector responses, including T-helper 1 and T-helper 17 pathways and antibody production, which attack what has been flagged as foreign.
• Regulatory responses, including regulatory T cells and anti-inflammatory signalling, which keep effector responses proportionate and prevent attack on self.

A compound can push one arm up and another down at the same time. It can behave differently in a healthy person, in someone with an infection, and in someone whose regulatory arm has already failed. That is why "this peptide modulates the immune system" is a description of uncertainty, not a reassurance.

Why up-regulation is the wrong goal in autoimmunity

In autoimmune disease, the defining failure is loss of self-tolerance. The effector arm is active against the body, and the regulatory arm has not contained it. Most treatment in rheumatology and related specialties therefore works by turning specific parts of the immune response down: corticosteroids, conventional disease-modifying drugs, biologics that block a particular cytokine, and newer targeted small molecules.

Against that background, a compound marketed to "boost" immunity is not neutral. If it increases innate sensing or effector activity, it is pushing in the direction of the disease.

This is not only a theoretical argument. There is a clear human example of what happens when immune activity is deliberately increased in people with autoimmune disease. Immune checkpoint inhibitors, cancer drugs that release brakes on T cells so they can attack tumours, have been given to patients with pre-existing autoimmune conditions, usually after careful specialist discussion. A 2024 systematic review and meta-analysis in BMC Cancer, pooling 23 studies and 643 patients with pre-existing rheumatologic autoimmune disease, found a flare of the existing disease in about 41% of patients, with rheumatoid arthritis flaring more often than other conditions. Most flares were mild to moderate, and these patients were treated with oncologists and often rheumatologists monitoring them.

Checkpoint inhibitors are far more potent than any peptide discussed here, and they are not being compared directly. The point is the direction of effect: in people with autoimmune disease, deliberately raising immune activity is known to wake the disease up.

Thymosin alpha-1 and LL-37: where the mechanism cuts both ways

Thymosin alpha-1

Thymosin alpha-1 is a thymus-derived peptide approved as Zadaxin in a number of countries outside the US, principally for chronic hepatitis B. It is not FDA-approved and is investigational in the United States.

Its best-characterised mechanism is on dendritic cells. Laboratory work by Romani and colleagues, published in Blood in 2006, showed that thymosin alpha-1 acts through Toll-like receptor 9 to prime dendritic cells toward a T-helper 1 response, the kind of response that helps clear infections. The same work showed that, in mouse dendritic cells, it also switched on indoleamine 2,3-dioxygenase (IDO), an enzyme that supports regulatory T cells and tolerance.

That combination is exactly why the word "both" matters. The pro-tolerance strand is what proponents point to when they suggest the peptide could calm autoimmunity. The Th1-priming, Toll-like-receptor strand is what a rheumatologist would worry about, because Th1 activity and Toll-like receptor signalling are part of how several autoimmune diseases are driven. Which strand dominates in a person whose tolerance has already failed is not known. Mouse and cell-culture findings cannot answer it.

A monograph submitted to a public FDA docket lists use in people who are being deliberately immunosuppressed as a contraindication. That is a reminder that, even among those who favour the compound, its interaction with immunosuppressive treatment is treated as a reason for caution.

LL-37

LL-37 is the only human cathelicidin, an antimicrobial peptide made by skin cells and neutrophils. It is part of normal innate defence. It is not FDA-approved and is on the docket for the next Pharmacy Compounding Advisory Committee review, which is not an approval.

LL-37 holds one of the clearest mechanistic links between a peptide and autoimmune disease in the immunology literature:

• Psoriasis. In a 2007 paper in Nature, Lande and colleagues showed that LL-37 binds fragments of the body's own DNA and carries them into plasmacytoid dendritic cells, where they trigger Toll-like receptor 9 and a burst of type I interferon. Self-DNA normally does not do this. LL-37 was identified as the key factor converting it into an alarm signal in psoriatic skin. Follow-up work in 2009 showed LL-37 does something similar with self-RNA.
• Lupus. In a 2011 paper in Science Translational Medicine, the same group showed that neutrophils from people with systemic lupus erythematosus release extracellular traps containing self-DNA complexed with antimicrobial peptides, LL-37 among them, and that these complexes activate plasmacytoid dendritic cells. Patients also made antibodies against the peptides themselves.

LL-37 also has documented anti-inflammatory and wound-healing actions in other settings, which is why it is marketed. But in the two diseases where its role has been studied most closely, it appears on the side of the pathology. This is mechanism evidence, not a trial, and it does not show what an administered peptide would do. It does show why the question cannot be answered by the word "immunomodulatory".

What the evidence does and does not establish

Two things follow. First, the absence of reported problems is not evidence of safety. People with autoimmune disease are routinely excluded from trials of immune-active agents, and autoimmune disease naturally fluctuates, so a flare weeks after starting something is easy to attribute to stress or chance. Second, the absence of trials is not evidence of harm. The honest position is that the risk is unmeasured: unestablished, not disproven, because the studies have not been funded or run. That is also the position for related questions covered in peptides for long COVID and MCAS, where similar immune-sensing pathways are involved.

Why this is a specialist conversation, not a self-assessment

Several things decide whether any immune-active compound is a reasonable discussion for a particular person, and almost none of them are visible from outside a clinic:

• The diagnosis and how active it is. A condition in stable remission and one in an active flare are different situations.
• Antibody status and baseline markers. These are what would show a change, and without a baseline, a flare cannot be measured against anything. General markers such as hs-CRP are not specific enough on their own.
• The current treatment. Many people with autoimmune disease take medicines that are designed to turn part of the immune system down. Adding something that may turn another part up introduces an unmeasured variable into a regimen that has been deliberately balanced. Whether it would pull against the treatment, add to it, or do nothing depends on the drug, the disease and the person, and that assessment belongs with the prescriber.
• History that has not been diagnosed yet. Positive thyroid antibodies on an old blood test, a strong family history, unexplained joint or skin symptoms. These matter because a primed immune system is where a push can tip a latent problem into a clinical one.

For most inflammatory joint, connective tissue and systemic conditions, the right specialist is a rheumatologist. For thyroid autoimmunity it is usually an endocrinologist; for inflammatory bowel disease, a gastroenterologist; for multiple sclerosis, a neurologist. The useful approach is to take the specific compound and the specific question to that person before starting anything, along with a full medication and supplement list.

There is a broader context too. Chronic, low-grade immune activation with age, discussed in inflammaging, is a different problem from autoimmunity, and advice written for one does not transfer to the other.

Frequently asked questions

Are peptides safe if you have an autoimmune disease? For immune-modulating peptides, safety in autoimmune disease has not been established. The relevant controlled trials have not been run, and people with autoimmune conditions are usually excluded from the studies that do exist. Mechanistic evidence shows that some of these peptides act on the same pathways that drive autoimmunity, and human data from other immune-activating drugs show that raising immune activity can trigger flares. That makes it a question for the specialist managing the condition, not a general yes or no.

What is the risk with thymosin alpha-1 in autoimmune disease? It is unmeasured. Laboratory studies show thymosin alpha-1 primes dendritic cells through Toll-like receptor 9 toward a Th1 response while also promoting tolerance through IDO. Which effect would dominate in someone whose immune tolerance has already failed is not known. It is not FDA-approved in the United States, and a monograph submitted to the FDA lists deliberate immunosuppression as a contraindication.

Why is LL-37 a concern in psoriasis and lupus? Because research has implicated it in how those diseases are driven. LL-37 can bind the body's own DNA or RNA and deliver it to plasmacytoid dendritic cells, which then release type I interferon as though responding to infection. This was shown in psoriatic skin and, for neutrophil-derived peptide complexes, in lupus. It is mechanism evidence and does not prove that administered LL-37 causes flares, but it is a strong reason for caution.

Can immune-modulating peptides interact with immunosuppressants? They have not been formally studied together, so the interaction is unknown. Immunosuppressive and disease-modifying treatments are dosed and monitored to balance disease control against infection risk. Anything that acts on the immune system adds a variable to that balance, which is why the prescriber needs to know before, not after.

If you are still weighing an immune-active peptide

Vivre Labs' compound pages for thymosin alpha-1 and KPV set out each compound's evidence and regulatory status, including what has and has not been studied. If you have an autoimmune diagnosis, read them as background for a conversation with the specialist who manages your condition, not as a starting point. Bring your history, current treatment and disease activity to that conversation; your specialist may advise against any immune-active compound for you.

Related reading

• Peptides for long COVID and MCAS - immune dysregulation and what the evidence supports
• Inflammaging - chronic low-grade inflammation with age, and why it is not autoimmunity
• LL-37 (cathelicidin) - what it is, and why the FDA is reviewing it next
• Part of The Complete Guide to Inflammation Management

---

Talk it through with a specialist first. If you live with an autoimmune condition, the conversation about any immune-active compound starts with the clinician who manages it, with your current treatment, antibody status and disease activity on the table. Vivre Labs recommends starting with baseline bloodwork, so any decision starts with the evidence and your existing care, not a product.

Educational content, not medical advice. This page does not recommend any compound for any person with an autoimmune condition, and no compound is presented as suitable or unsuitable for an individual. Thymosin alpha-1 is approved in some countries outside the United States, principally for chronic hepatitis B, and is not FDA-approved; LL-37 is not approved for any indication and is not on the 503A Bulks List. Both are investigational in the United States. Checkpoint inhibitors are discussed only as published evidence about the effect of immune activation in autoimmune disease. No doses, schedules, protocols, sourcing or drug-by-compound interaction guidance appear on this page. Do not stop or change any prescribed treatment without speaking to the prescriber. Claims for the Malaysian market are subject to MAB requirements. Position stated as of 19 October 2026.

References

• Checkpoint inhibitors and pre-existing autoimmune disease - Immune checkpoint inhibitors in cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis. BMC Cancer. 2024. (23 articles, 643 patients; pooled flare incidence 41%; grade 3-4 flares 7%; rheumatoid arthritis flared more than other rheumatologic conditions.) (PubMed Central)
• Thymosin alpha-1 mechanism - Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-2274. (Toll-like receptor 9-dependent Th1 priming of dendritic cells; IDO induction, IL-10 and regulatory T cell generation in mouse dendritic cells.)
• Thymosin alpha-1 contraindication - Thymosin alpha-1 monograph submitted to FDA docket FDA-2024-N-4777: "Do not use in individuals being deliberately immunosuppressed." (regulations.gov)
• LL-37 in psoriasis - Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564-569. · Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. Journal of Experimental Medicine. 2009;206(9):1983-1994.
• LL-37 and lupus - Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Science Translational Medicine. 2011;3(73):73ra19.
• Regulatory status - Thymosin alpha-1 (Zadaxin) approved outside the United States, principally for chronic hepatitis B; not FDA-approved. LL-37 not FDA-approved and not on the 503A Bulks List; listed for the second PCAC review expected before the end of February 2027, no date set.